Advances in Biomarkers for Risk Stratification in Barrett's Esophagus

Rhonda F. Souza; Stuart Jon Spechler

doi:10.1016/j.giec.2020.08.007

Advances in Biomarkers for Risk Stratification in Barrett's Esophagus

Rhonda F. Souza, Stuart Jon Spechler

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

Dysplasia currently is the primary biomarker used to risk stratify patients with Barrett's esophagus, but dysplasia has a number of considerable limitations in this regard. Thus, investigators over the years have explored innumerable alternative molecular biomarkers for risk stratification in Barrett's esophagus. This report focuses only on those biomarkers that appear most promising based on the availability of multiple published studies corroborating good results, and on the commercial availability of the test. These promising biomarkers include p53 immunostaining, TissueCypher, BarreGEN, and wide-area transepithelial sampling with computer-assisted 3-dimensional analysis (WATS^3D).

Original language	English (US)
Pages (from-to)	105-115
Number of pages	11
Journal	Gastrointestinal Endoscopy Clinics of North America
Volume	31
Issue number	1
DOIs	https://doi.org/10.1016/j.giec.2020.08.007
State	Published - Jan 2021
Externally published	Yes

Keywords

Dysplasia
Esophageal adenocarcinoma
Mutational load
Systems biology
p53

ASJC Scopus subject areas

Gastroenterology

Access to Document

10.1016/j.giec.2020.08.007

Cite this

@article{d45a63c324c846569c4960be5db96556,

title = "Advances in Biomarkers for Risk Stratification in Barrett's Esophagus",

abstract = "Dysplasia currently is the primary biomarker used to risk stratify patients with Barrett's esophagus, but dysplasia has a number of considerable limitations in this regard. Thus, investigators over the years have explored innumerable alternative molecular biomarkers for risk stratification in Barrett's esophagus. This report focuses only on those biomarkers that appear most promising based on the availability of multiple published studies corroborating good results, and on the commercial availability of the test. These promising biomarkers include p53 immunostaining, TissueCypher, BarreGEN, and wide-area transepithelial sampling with computer-assisted 3-dimensional analysis (WATS3D).",

keywords = "Dysplasia, Esophageal adenocarcinoma, Mutational load, Systems biology, p53",

author = "Souza, {Rhonda F.} and Spechler, {Stuart Jon}",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",

year = "2021",

month = jan,

doi = "10.1016/j.giec.2020.08.007",

language = "English (US)",

volume = "31",

pages = "105--115",

journal = "Gastrointestinal Endoscopy Clinics of North America",

issn = "1052-5157",

publisher = "W.B. Saunders Ltd",

number = "1",

}

TY - JOUR

T1 - Advances in Biomarkers for Risk Stratification in Barrett's Esophagus

AU - Souza, Rhonda F.

AU - Spechler, Stuart Jon

PY - 2021/1

Y1 - 2021/1

N2 - Dysplasia currently is the primary biomarker used to risk stratify patients with Barrett's esophagus, but dysplasia has a number of considerable limitations in this regard. Thus, investigators over the years have explored innumerable alternative molecular biomarkers for risk stratification in Barrett's esophagus. This report focuses only on those biomarkers that appear most promising based on the availability of multiple published studies corroborating good results, and on the commercial availability of the test. These promising biomarkers include p53 immunostaining, TissueCypher, BarreGEN, and wide-area transepithelial sampling with computer-assisted 3-dimensional analysis (WATS3D).

AB - Dysplasia currently is the primary biomarker used to risk stratify patients with Barrett's esophagus, but dysplasia has a number of considerable limitations in this regard. Thus, investigators over the years have explored innumerable alternative molecular biomarkers for risk stratification in Barrett's esophagus. This report focuses only on those biomarkers that appear most promising based on the availability of multiple published studies corroborating good results, and on the commercial availability of the test. These promising biomarkers include p53 immunostaining, TissueCypher, BarreGEN, and wide-area transepithelial sampling with computer-assisted 3-dimensional analysis (WATS3D).

KW - Dysplasia

KW - Esophageal adenocarcinoma

KW - Mutational load

KW - Systems biology

KW - p53

UR - http://www.scopus.com/inward/record.url?scp=85094619980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85094619980&partnerID=8YFLogxK

U2 - 10.1016/j.giec.2020.08.007

DO - 10.1016/j.giec.2020.08.007

M3 - Review article

C2 - 33213790

AN - SCOPUS:85094619980

SN - 1052-5157

VL - 31

SP - 105

EP - 115

JO - Gastrointestinal Endoscopy Clinics of North America

JF - Gastrointestinal Endoscopy Clinics of North America

IS - 1

ER -

Advances in Biomarkers for Risk Stratification in Barrett's Esophagus

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this